Swog S1806 Phase III Randomized Trial Of Concurrent Chemoradiotherapy With Or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer
Posted Date: May 22, 2020
- Investigator: Robert Franklin
- Specialties: Cancer, Oncology
- Type of Study: Drug
The primary goal of this study is to compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC)
Criteria:
To Be Eligible: Must Have Urothelial Carcinoma Of The Bladder, Undergo Radiological Staging Within 70 Days, Zubrod Performance Status = 2, No Prior Malignancy Except Non-Melanoma Skin Cancer, No Systemic Chemotherapy For Bladder Cancer, No Major Surgery Within 28 Days,
Keywords:
Bladder Cancer, Chemoradiotherapy
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com